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Abstract 
 Diffuse axonal injury (DAI) is a common feature of severe traumatic brain injury (TBI) 
and may also be a predominant pathology in mild TBI or “concussion”. The rapid deformation 
of white matter at the instant of trauma can lead to mechanical failure and calcium-dependent 
proteolysis of the axonal cytoskeleton in association with axonal transport interruption.  
Recently, a proteolytic fragment of alpha-II spectrin, “SNTF”, was detected in serum acutely 
following mild TBI in patients and was prognostic for poor clinical outcome. However, direct 
evidence that this fragment is a marker of DAI has yet to be demonstrated in either humans 
following TBI or in relevant animal models of TBI.  Here we used immunohistochemistry (IHC) 
to examine for SNTF in brain tissue following both severe and mild TBI.  Human severe TBI 
cases (survival <7d; n=18) were compared to age-matched controls (n=16) from the Glasgow 
TBI archive. We also examined brains from an established swine model of mild TBI at 6h, 48h 
and 72h post-injury versus shams. IHC specific for SNTF was compared to that of amyloid 
precursor protein (APP), the current standard for DAI diagnosis, and other known markers of 
axonal pathology including non-phosphorylated neurofilament-heavy (SMI-32), neurofilament-
68 (NF-68) and compacted neurofilament-medium (RMO-14). Supporting its use as a 
biomarker of DAI, SNTF immunoreactive axons were observed at all time-points following both 
human severe TBI and in the model of mild TBI. Interestingly, SNTF revealed a subpopulation 
of degenerating axons, undetected by the gold-standard marker of transport interruption, APP. 
While there was greater axonal co-localization between SNTF and APP after severe TBI in 
humans, a subset of SNTF positive axons displayed no APP accumulation. Notably, some co-
localization was observed between SNTF and the less abundant neurofilament subtype 
markers, predominantly RMO-14. Other SNTF positive axons, however, did not co-localize. 
Similarly, RMO-14 positive axonal pathology existed independent of SNTF and APP. These 
data demonstrate that multiple axonal phenotypes exist post-TBI and provide insight into a 
more comprehensive approach to the neuropathological analyses of DAI.  
 
 
 
 
Keywords: traumatic brain injury; TBI; concussion; mild TBI; diffuse axonal injury; spectrin 
breakdown; SNTF; axonal pathology; amyloid precursor protein. 
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Introduction 
 Traumatic brain injury (TBI) is recognized as a major public health problem, inflicting 
substantial burden on individuals, their families and economies worldwide [16, 18, 30, 32]. 
Moreover, emerging data describing persistent symptoms and the potential for chronic 
neurodegenerative consequences from mild TBI (mTBI) or “concussion” has ignited 
considerable public concern [71]. 
 Axons are especially vulnerable to the mechanical loading of the brain during trauma, 
making diffuse axonal injury (DAI) one of the most common pathologies of TBI [1-3, 25, 35]. 
Specifically, rapid acceleration / deceleration caused by rotational forces at the moment of 
injury precipitate brain pathology via shear, tensile, and compressive strains [21, 43].  Although 
axons rarely disconnect at the time of head impact, even in severe TBI, the dynamic 
deformation of white matter can cause immediate or primary disruption of the axonal 
cytoskeleton [35, 78, 79].  In addition, multiple evolving neurochemical changes are induced by 
TBI, including rapid and progressive elevations in intra-axonal calcium [10, 33, 39, 50, 74, 80, 
82].   At pathological levels, the calcium overload activates the calcium-dependent calpain 
proteases, which can in turn initiate catastrophic secondary damage to the axon [13, 36, 42, 
56, 57, 68, 74, 80].    
A well-characterized consequence of axonal cytoskeletal disruption is the interruption of 
axonal transport, leading to accumulation of transported proteins in axonal swellings. Indeed, 
visualization of the accumulation of amyloid precursor protein (APP) in damaged axons is the 
current gold-standard neuropathological approach for the diagnosis of DAI [23, 35, 59].  
Interestingly, while all axons of a given white matter tract endure similar high strains and strain 
rates during TBI, only a subset of the total axonal population accumulates APP. This suggests 
that this putative marker of axonal pathology may not identify all injured axons at any given 
time post-TBI.  Indeed, previous work in rodents indicates that a marker for compacted 
neurofilament-medium (RMO14) identifies injured axons that do not accumulate APP [77]. 
 While DAI was largely thought to be a consequence of moderate or severe TBI, 
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emerging evidence suggests that it may also be the predominant pathology of mild TBI [5-7, 
40, 44, 81, 84]. In particular, advanced neuroimaging studies of mTBI patients consistently 
identify white matter changes, the extent of which appear to determine clinical outcome [17, 44, 
45, 62].  In addition, following a swine model of head rotational acceleration scaled to human 
mTBI parameters, DAI was the most notable pathology [8].   
Recent studies evaluating blood biomarkers have provided further evidence in support of 
axonal damage in mTBI. Specifically, elevations in the axon-enriched microtubule-associated 
protein tau have been demonstrated in the blood of professional ice hockey players with 
sports-related concussion [58]. In this same cohort, serum elevations of a proteolytic fragment 
of the axon-specific protein, spectrin, were detected and correlated with the severity of post-
concussion symptoms [65].  In another mTBI cohort, acute serum levels of this same spectrin 
fragment identified patients who went on to have persisting neurocognitive dysfunction [62]. 
This blood biomarker is the 1176 residue of calpain-derived alpha-II spectrin N-terminal 
fragment, or “SNTF”, and its genesis likely reflects injury-induced elevations in intra-axonal 
calcium and activation of calpain [80].  
 While SNTF has been detected using Western blotting in brain tissue from severe TBI 
patients [41], the specific anatomical source of SNTF has yet to be demonstrated in humans 
following TBI of any severity or in any models of mTBI.  Nonetheless, SNTF has been 
observed to accumulate in axons acutely after moderate to severe TBI in small animal models 
and with in vitro models of neuronal trauma [13, 42, 56, 57, 80].  Interestingly, SNTF has been 
demonstrated to co-localize with RMO14 immunroeactivity indicating compacted 
neurofilaments in rodent models [13]. However, the relative role of SNTF as a marker of DAI 
when compared to the gold-standard, APP, has not been explored. Moreover, potential co-
localization with RMO14 or other neurofilament subtypes has not been examined in humans or 
larger animal models of mTBI. 
Here, we performed neuropathological examinations of SNTF immunostaining after mild 
and severe TBI.  Since mild TBI in humans is rarely fatal, and thus tissue is unavailable for 
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acute post-mortem analysis, we used a parallel approach of examining brain sections of single 
severe TBI in humans as well as from an established swine model of mild TBI. SNTF 
immunohistochemistry was compared to that of APP and various neurofilament subtypes to 
permit comparison with the current standard for DAI diagnosis. 
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Methods 
Non-Impact Rotational Acceleration Model of Mild TBI in Swine 
 All animal experiments were conducted in accordance with protocols approved by The 
University of Pennsylvania Institutional Animal Care and Use Committee. The University of 
Pennsylvania is accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC). 6-month-old female Hanford miniature swine (23-36kg) were 
subjected to the established non-impact rotational acceleration injury model as described in 
detail previously [8, 43, 55, 69, 72]. Briefly, following induction using 0.4mg/Kg midazolam IM 
and 5% inhaled isoflurane, animals were intubated and anesthesia maintained via 2.5% 
inhaled isoflurane. The HYGE pneumatic actuator device was then used to induce rapid head 
rotation. Specifically, the HYGE actuator generates linear motion via the triggered release of 
pressurized nitrogen. This linear motion is then converted to angular motion via custom 
designed linkage assemblies to induce rotation of up to 110o within 20 msec. Rotational 
kinematics were recorded using angular velocity transducers (Applied Technology Associates, 
Albuquerque, NM) mounted to the linkage sidearm coupled to a National Instruments (Austin, 
TX) data acquisition system running custom LabView software (10 kHz sampling rate). In this 
fashion, we produced pure impulsive centroidal head rotation in the coronal plane with peak 
angular velocity of 207-247rad/sec. Animals were recovered from anesthesia and returned to 
the housing facility. While the procedure is non-surgical, preemptive analgesia was provided 
post-injury in the form of 0.3mg of buprenorphine (slow release preparation) SQ and 
acetaminophen 50mg/Kg PR 6 hourly. 
 Animals were euthanized at 6 hours (n=3), 48 hours (n=2) and 72 hours (n=3) post-injury 
and compared to sham animals (n=3) euthanized at 72 hours post-sham-injury. Specifically, all 
animals were deeply anesthetized and transcardially perfused using heparinized saline (4L) 
followed by 10% neutral buffered formalin (NBF) (8L). The brain was subsequently removed 
and post-fixed for 7 days in 3L of 10% NBF. The whole brain was dissected into 5mm blocks in 
coronal plane and processed to paraffin using standard techniques.  
Page 7 of 40 
 
Human Post-Mortem Acute Severe TBI Cohort: Demographic and Clinical Data 
 All tissue was obtained from the Glasgow TBI Archive, Department of Neuropathology, 
Queen Elizabeth University Hospital, Glasgow, UK.  Tissue was acquired at routine diagnostic 
autopsy and approval for use was granted by the NHS Greater Glasgow and Clyde Bio-
repository Governance Committee. For this type of study formal consent is not required. 
 TBI cases were selected to include patients who died acutely following severe TBI, with 
survival times ranging from 6 hours to 1 week (median 90 hours; n=18). Detailed reports from 
the diagnostic autopsy and/or forensic reports were available for all cases and indicated a 
history of a single severe TBI, supported by autopsy findings. TBI cases were compared to 
material from age/sex-matched controls (n=16) acquired at routine diagnostic post-mortem at 
the same institution. Controls had no documented history of TBI. Full clinical and demographic 
information, including age, sex and cause of death, is provided for all groups in Table 1. 
 
Human Brain Tissue Preparation 
 For all examinations, the intact brain was immersed in 10% formol saline at autopsy and 
fixed for at least 3 weeks prior to dissection. Sampling using a standardized protocol and 
paraffin embedding was performed as described previously [26]. Analyses were performed 
using hemi-coronal sections of the parasagittal cortex at the level of the mid-thalamus to 
include the cingulate gyrus and corpus callosum. This region was selected given its midline 
location and known susceptibility to DAI [1, 2, 34, 35, 37]. 
 
Immunohistochemical Labeling of Human and Swine Tissue 
 Paraffin embedded tissue from both swine rotational injury studies and human post-
mortem studies were subjected to routine histology including H&E staining as well as 
immunohistological techniques as described below. All tissue examinations were performed on 
8µm sections. 
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Single Immunohistochemical Labeling: Following deparaffinization and rehydration, sections 
were immersed in aqueous hydrogen peroxide (10 minutes) to quench endogenous peroxidase 
activity. Antigen retrieval was performed in a microwave pressure cooker with immersion in Tris 
EDTA buffer. Subsequent blocking was achieved using 50µl of normal horse serum (Vector 
Labs, Burlingame, CA, USA) per 5ml of Optimax buffer (BioGenex, San Ramon, CA, USA) for 
30 minutes. Incubation with the primary antibodies was performed for 20 hours at 4oC. 
Specifically, Ab2233, rabbit serum reactive with the calpain-generated neoepitope at the 
carboxyl-end of the calpain-derived ±-spectrin N-terminal fragment, SNTF (αII-spectrin 
residues 1-1176) [54, 62] was applied at 1:12K (human) and 1:17.5K (swine). The specificity of 
this cleavage site-specific antibody for SNTF generated by calpain proteolysis has been well 
established by Western blot, protease digest, and protease inhibitor studies [54, 61, 63, 66, 
67]. As additional confirmation of the specificity of the antibody, an additional subset of sections 
from both human TBI cases and the swine were also labeled with independent antiserum 
generated in different rabbits. This included Ab37 [57] and Ab2234 (which was subjected to 
antigen-affinity purification).  A synthetic peptide corresponding to the calpain-generated 
neoepitope in SNTF (CAQQEVY) was conjugated covalently to maleimide-activated Sepharose 
via the cysteine side chain and the resulting resin used for affinity purification of SNTF-specific 
antibodies.  
 Adjacent, serial sections were labeled with an antibody reactive for the N-terminal amino 
acids 66-81 of the amyloid precursor protein (APP) (Millipore, Billerica, MA) at 1:50K (human) 
or 1:80K (swine) as the current gold standard for the clinico-pathological detection of axonal 
pathology [22, 59].  Specifically, axonal pathology is identified by visualizing APP accumulating 
within axonal bulbs or swollen and tortuous varicosities along the length of damaged axons 
with transport interruption. Mouse monoclonal antibodies specific for additional neurofilament 
subtype markers of axonal injury were also applied to all animals and human cases including 
compacted neurofilament-M (RMO-14; Cell signaling technology, Danvers, MA.) at 1:1K, non-
phosphorylated neurofilament-H (SMI-32 [76]; Biolegend, San Diego, CA) at 1:300 and NF-68 
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(Biosensis, Thebarton, Australia.) at 1:500.  After rinsing, sections were incubated with the 
appropriate biotinylated secondary antibody for 30 minutes (Vectastain Universal Elite kit, 
Vector Labs, Burlingame, CA, USA), followed by an avidin biotin complex as per the 
manufacturer’s instructions (Vectastain Universal Elite kit, Vector Labs, Burlingame, CA, USA). 
Finally, visualization was achieved using the DAB peroxidase substrate kit, as per 
manufacturer’s instructions (Vector Labs, Burlingame, CA, USA). Counterstaining with 
haematoxylin was performed and sections were examined using light microscopy on a Nikon 
Eclipse 80i microscope (Nikon, Tokyo, Japan).  Positive control tissue for IHC included 
sections containing the corpus callosum from a case of previously established DAI. Omission 
of the primary antibody was performed on the same material to control for non-specific binding.  
 
Double and Triple Immunofluorescence Labeling: Following single immunolabeling, a 
subset of SNTF positive human cases (n=6) and all swine studies were selected for further 
examination by double or triple fluorescent immunolabeling with SNTF and APP, 
neurofilament-200 (NF-H), non-phosphorylated NF-H, NF-L and compacted neurofilament-M. 
Specifically, following deparaffinization and rehydration of sections, antigen retrieval and 
blocking were performed as described above. The same anti-SNTF antibody was applied 
overnight (4oC) at 1:7.5K (pig) and 1:1K (human). After rinsing, sections were incubated in a 
biotinylated donkey anti rabbit secondary antibody (Vector Labs, Burlingame, CA, USA) for 30 
minutes followed by a streptavidin, Alexa Fluor 568 conjugate for 2 hours at room temperature. 
Next, the following antibodies were applied serially overnight at 4oC including mouse anti-APP 
antibody (Millipore, Billerica, MA) at 1:8K, goat anti-APP (Cephalon; PA, [60, 85]) at 1:1K, 
mouse anti-NF-H (Sigma, St Louis, MO) at 1:1.8K, RMO-14 (Cell signaling technology, 
Danvers, MA.) at 1:50,  non-phosphorylated neurofilament-H (SMI-32; Biolegend, Dan Diego, 
CA) at 1:50 and NF-68 (Biosensis, Thebarton, Australia.) at 1:75. The corresponding Alexa 
Fluor 488 donkey anti-mouse or donkey ant goat 647 IgG secondary antibodies were applied 
for 2 hours at room temperature. Following rinsing, sections were coverslipped using 
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fluorescence mounting medium (Dako, Carpinteria, CA) and visualized using a confocal Nikon 
Eclipse Ti microscope (Nikon, Tokyo, Japan). 
Analysis of Immunohistochemical Findings 
All observations were conducted blind to demographic and clinical information by 2 
independent observers (VJ and WS).  Cases were reviewed independently and inter-rater 
reliability was >90%. Those slides where there was disagreement were reviewed by both 
observers until consensus was reached. 
 The extent and morphology of axonal pathology was evaluated by generating detailed 
maps of both SNTF and APP immunoreactivity in order to (1) determine the pattern of SNTF 
staining in damaged axons and (2) permit comparison with the current gold standard means of 
identifying axonal pathology (APP IHC).  Semi-quantitative analyses of pig tissue was 
performed blind to the injury status on the whole coronal brain section at the level of the lateral 
ventricles in Fig. 1a. Whole coronal tissue sections were assessed grouped ranked into 4 
groups has having 0 = no pathology; 1 = minimal pathology with less than 500 individual 
injured axonal profiles across the section 2 = moderate pathology (500-1000 profiles) and 3 = 
extensive pathology (>1000 profiles). An injured axonal profile consisted of a varicose axon or 
individual axonal bulbs / fragments. 
Additionally, in human TBI cases, the extent of axonal pathology as revealed by both 
SNTF and APP staining was then classified using standard semi-quantitative assessments as: 
0=absent, 1=minimal 2=moderate or 3=extensive pathology. This scoring was representative of 
the entire hemi-coronal section of the parasagittal cortex at the level of the mid-thalamus to 
include the cingulate gyrus and corpus callosum.   
 
Statistical Analyses 
Statistical analyses were performed using GraphPad Prism statistical software (GraphPad 
Software Inc. La Jolla, CA). The Fisher’s Exact test was used to assess differences in the 
presence of axonal pathology between human TBI cases versus controls. 
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Results 
 
Clinical Presentation Following mTBI in Swine 
 After being returned to housing (within 30 minutes of injury), all animals regained 
consciousness and mobilized rapidly (within 5-10 minutes) following withdrawal of isoflurane, 
indicating that there was no prolonged loss of consciousness. Following recovery from 
anesthesia, all animals were fully conscious and alert. Mental status was unaltered and all 
animals resumed normal feeding and drinking behavior within 1-2 hours. Consistent with the 
clinical presentation of mild TBI, all animals had a normal neurological examination and did not 
display any focal neurological deficits. Specifically, the animals displayed normal posture, tone, 
gait, power, sensation and proprioception. Examination of cranial nerves was normal. 
 
Gross Neuropathological Examination and H&E Staining Following Rotational 
Acceleration Injury in Swine 
 Following rotational injury, the brains of all animals were normal on gross pathological 
examination and indistinguishable from sham animals. Consistent with mild TBI clinically, there 
was no evidence of any focal lesions, including hemorrhagic lesions. In addition, the 
hemispheres were symmetrical with no evidence of brain swelling or raised intracranial 
pressure (ICP). Consistent with these observations, H&E staining demonstrated an absence of 
any hemorrhagic or ischemic lesions, or neuronal pyknosis in any animals. 
 
Axonal Pathology (APP IHC) Following Rotational Acceleration Injury in Swine 
 Examination using IHC specific for APP revealed swollen and morphologically altered 
axons consistent with transport interruption secondary to axonal cytoskeletal damage and 
indistinguishable from those observed in human DAI [1-3, 22, 23, 34, 35, 59] (Fig. 1). 
Specifically, many axonal APP positive profiles had the appearance of large spheroids and, 
while dependent on the plane of view, likely represent disconnected axon terminals. In 
contrast, other APP reactive axons displayed a more fusiform or varicose morphology, often 
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with multiple swellings along the axon length and greatly increased in diameter (Fig. 1b-h). 
Much more rarely, axons with limited APP accumulation and an undulating morphology were 
observed, although predominant only at the most acute survival time point (6 hours post-injury). 
Mapping of APP immunoreactive axons with an abnormal morphology releveled these to be 
consistently observed in a stereotypical, multifocal distribution affecting the subcortical and 
periventricular white matter and midline structures of all injured animals (Fig. 1a). Notably, the 
pattern and distribution of pathology was not symmetrical, with the left hemisphere (the leading 
hemisphere during coronal rotation) displaying an increased density of pathology in the deep 
white matter and with extensive pathology in the periventricular white matter of the lateral 
ventricles. In contrast, the right (non-leading) hemisphere displayed more frequent axonal 
pathology in the digitate white matter rostrally (Fig. 1a). This hemisphere-dependent 
distribution of pathology was conserved between animals and consistent with a direct 
mechanical etiology. Moreover, injured axons were frequently observed underlying or around 
vessels which, as comparatively rigid structures, can injure axons during dynamic brain 
deformation (Fig. 1f). 
 Consistent with previous examinations in both animal models and clinical DAI [23, 34, 
35, 59], axonal pathology was observed at all time-points post-injury from 6-72 hours. Notably, 
while the distribution was the same at 6 hours post-injury, the extent of pathology and the size 
of axonal swellings was not as marked when compared to that following 48-72 hours survival. 
As all animals were injured with the same input parameters, resulting in a tight range of peak 
rotational velocities for each study, the resultant neuropathological outcome was highly 
consistent between animals. Maps of pathology indicated virtually identical pattern and 
distribution of APP pathology between all animals at each time point. Moreover, semi-
quantitative rating of the extent of pathology was also highly consistent between all animals at 
all time points. Specifically all animals examined at 6 hours post mTBI had less than 500 
profiles. However by 48-72 hours, all animals had a score of 2 or 3. Notably, the animals with a 
score of 3 at 48-72 hours had slightly higher rotation levels that would account for the 
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increased pathology observed. No axonal pathology was observed in any sham animals using 
APP IHC. 
 
SNTF Immunoreactivity Following Rotational Acceleration Injury in Swine 
 Following rotational acceleration injury, SNTF positive structures with the morphological 
appearance of axons were found in the white matter in a pattern and distribution identical to 
that observed using APP immunohistochemistry as described above. Double labeling with the 
axonal marker NF-H identified the SNTF positive structures as axons (Fig. 3j-o). The specificity 
of the axonal immunoreactivity for SNTF was confirmed in a subset of serial sections using an 
additional independent antiserum, Ab37, and the antigen-affinity purified SNTF antibody 
Ab2234. All 3 antibodies revealed highly consistent patterns of immunoreactivity for axonal 
profiles with altered morphologies (undulations, swellings, degeneration) in the injured animals 
that were absent in sham animals. 
 Interestingly, SNTF positive axons were frequently of a much smaller diameter than 
typically observed with APP IHC. At 6 hours post-injury SNTF immunoreactivity was frequently 
observed in a confluent or patchy distribution along axons that appeared intact and without 
notable varicosities or swellings (Fig. 2b-j). However, several axons displayed an undulating 
morphology (Fig. 2e). In contrast, by 48 and 72 hours post-injury, virtually all SNTF positive 
axons displayed a more pathological phenotype with occasional small swellings and beading, 
indicative of a rapid degenerative process (Fig. 2f,g,I,k). Overall, the extent of pathology was 
less than observed using APP IHC, not only as a consequence of the much smaller non-
swollen profiles, but with fewer profiles overall. Specifically, semi-quantitaive analyses revealed 
that SNTF at all survival intervals in injured animals met the criteria for minimal pathology 
(score 1). In contrast, while APP pathology was minimal (score 1) at 6 hours, by 48 and 72 
hours survival, all animals displayed either moderate to extensive pathology (score 2-3) (Fig. 
2l). Notably, there was no SNTF immunoreactivity in neuronal cell bodies or dendrites at any 
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time point examined. No axonal pathology was observed in any sham animals using SNTF 
IHC. 
 
SNTF and APP Double Labeling Following Rotational Acceleration Injury in Swine 
 Double labeling IHC was performed specific to both SNTF and APP to evaluate their 
potential co-localization. Interestingly, in large part APP and SNTF appeared to identify 
different axonal populations. Specifically, while occasional co-localization between APP and 
SNTF was present in damaged axons, frequent APP positive / SNTF negative axons were 
observed (Fig. 3a-f). In addition, SNTF positive / APP negative axons were also identified (Fig. 
3g-i).  Notably, this was observed at all time-points examined from 6 hours – 72 hours post-
injury suggesting that SNTF may be identifying an axonal population distinct from APP positive 
axons in the traumatically injured brain. 
 
Comparison of SNTF with APP and Neurofilament Subtypes as Markers of Axonal 
Pathology following mTBI in Swine 
Previous work in both animal models and humans has demonstrated that 
immunohistochemistry examining various neurofilament subtypes can identify axonal pathology 
with varying degrees of success.   Given the above observation that SNTF positive axons can 
exist in the absence of APP accumulation, we next sought to determine whether neurofilament 
IHC identifies yet another distinct population of axons or if there was overlap of neurofilament 
subtype markers with APP or SNTF.  As such, we performed series of triple labeling studies 
with SNTF, APP and each of three previously identified markers including dephosphrylated NF-
H (SMI-32) [24, 56, 83], NF-68 [15, 24, 48, 83] and NF-M (RMO-14) [9-11, 13, 51, 77] to 
explore the relative role of these markers in identifying damaged axons.  
 
Non-phosphorylated NF-H (SMI-32): Consistent with previous work [24, 83], swine 
demonstrated normal immunoreactivity for non-phosphorylated NF-H in subgroups of neurons, 
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including staining in the cell body, dendrites and axons. This was consistent between both 
sham and injured animals. However, upon examination following mTBI in swine, SMI-32 did not 
readily identify axons with an altered morphology, even in regions identified to have dense 
pathology identified using APP on serial sections. This finding was independent of antibody 
concentration (data not shown). Notably, this finding is also consistent with previous work 
demonstrating that identification axonal pathology in swine using SMI-32 is relatively 
unsuccessful versus that described in rodent models [56, 69]. 
As observed in single labeled sections in the pig, triple immunofluorecent labeling 
performed with SMI-32, SNTF and APP demonstrated independent populations of SNTF and 
APP positive injured axons. While some co-localization could be observed with SNTF in non-
swollen, SMI-32 positive axons, there were no swollen or morphologically altered SMI-32 
positive axons that were distinguishable from those observed in shams. (Fig. 4). Interestingly, 
in some cases SMI-32 positive axons with a normal morphology were observed feeding into a 
terminal bulb that was densely APP positive, yet with a clear absence of SMI-32 accumulation 
in the terminal bulb itself  (Fig. 4a,e). 
 
NF-68: NF-68 immunoreactivity was present in axons and occasional dendrites, with a normal 
morphology in both sham and injured animals (Fig. 5a,1,n). However, following injury, in 
addition to axons with a normal appearance, single labeling with NF-68 revealed occasional 
large swollen axonal profiles consistent with the appearance of terminal axonal bulbs as has 
been previously described in swine and other models, as well as humans [15, 24, 48, 83] (Fig. 
5b,c-k). These were observed in regions consistent with biomechanical injury, and although 
were observed at 6 hours post-TBI, were notably more numerous by 48-72 hours post-TBI. In 
addition, NF-68 identified considerably less overall pathology, predominantly large swellings, 
when compared to serial sections labeled with APP. Indeed, the baseline axonal staining in 
normal limited interpretation of more subtle swellings or accumulations. Subsequent triple 
labeling studies with SNTF, APP and dephosphorylated NF-68 demonstrated that NF-68 
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positive bulbs could occasionally be observed overlapping in terminal bulbs with both SNTF 
and APP (Fig. 5h-k). However, at all time points all 3 markers identified injured axons in the 
absence of either of the other markers, identifying 3 novel populations of pathological axons at 
any given time (Fig. 5d-k). Notably, while NF-68 and APP identified larger swollen profiles, 
axons that were positive for SNTF only, were typically of smaller diameter and / or beaded as 
described above. 
Compacted Neurofilament-M (RMO-14): Immunoreactivity for RMO-14 was present in 
subgroups of neurons and axons with a normal morphology, consistent between sham and 
injured animals (Fig. 6a-c). Following mTBI, labeling for RMO 14 identified swollen axonal 
bulbs in regions consistent with biomechanical injury at all time-points (Fig. 6d-g). However, as 
with NF-68, the extent of pathology identified was minimal when compared to that identified 
using APP.  
Nonetheless, triple labeling with SNTF, APP and RMO-14.9 again demonstrated 
some minimal overlap with APP and SNTF populations of injured axons, virtually always in 
terminal bulbs. Here again, all 3 markers identified axons with an altered morphology in the 
absence of co-localization with either of the other markers (Fig. 6d-g). 
  
Axonal Pathology Identified by APP IHC Following TBI in Humans 
 APP IHC revealed axonal pathology in 17 of 18 (94%) of TBI cases versus 3 of 16 (19%) 
controls (p=<0.0001). APP immunoreactivity was observed from 6 hours to 7 days post-TBI in 
the form of classic terminal axonal bulbs and swollen fusiform profiles as has been previously 
described in detail [22, 34, 35, 59] (Fig. 7a). As expected, a range of patterns and distributions 
of pathology were observed. This included APP positive axons in a pattern and distribution 
consistent with traumatic diffuse axonal injury, with axonal profiles observed individually 
scattered or in small clusters, often in a single directional plane. In contrast, other cases 
displayed superimposed, widespread waves of axonal APP immunoreactivity in keeping with 
axonal pathology as a result of the vascular complications of raised intracranial pressure [19, 
20, 27, 29, 34, 53].  
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 Of the APP positive TBI cases, 2 (12%) displayed minimal axonal pathology with few 
scattered or isolated foci of pathological regions (score 1). 6 cases (35%) had moderate axonal 
pathology with multiple foci of APP positive axons in both dense regions associated with 
lesions or diffusely scattered axons (score 2) and the final 9 cases (53%) displayed extensive 
axonal pathology (score 3) with numerous foci of pathology and widespread and diffuse 
pathology occupying all regions of white matter examined (Fig. 7c). This compared to controls 
where just 1 case (6.25%) displayed moderate APP immunoreactivity (score 2) and 2 cases 
(12.5%) displayed minimal pathology (score 1). Notably, these controls displayed axonal 
pathology in a pattern and distribution in keeping with hypoxic/ischemic injury, likely indicative 
of an agonal event near the time of death [19, 20, 27, 29, 34, 53]. 
 
SNTF Immunoreactivity Following TBI in Humans  
SNTF immunoreactive axonal profiles with a morphological appearance consistent with injured 
and degenerating axons were observed in 17 of 18 (94%) TBI cases versus just 2 of 16 
(12.5%) controls (p=<0.0001). SNTF immunoreactive axons with an abnormal morphology 
were identified in cases across the survival range from 6 hours to 7 days post-injury and 
corresponded to the cases that had APP positive injured axons. Notably, SNTF axons 
displaying the classical appearance of swollen, fusiform axons and terminal axonal bulbs were 
observed and similar to those described using APP IHC (Fig. 7b). In addition, several early 
acute cases displayed axons with an undulating morphology (Fig. 8a-b).  Notably, fewer 
smaller diameter axons were observed when compared with the swine model of mild TBI.  
 Using the maps of pathology generated, the pattern and distribution of pathology 
identified using SNTF IHC correlated almost completely with the distribution of APP 
immunoreactive axonal pathology with respect to both region and pattern. Of the SNTF positive 
TBI cases, 6 cases (35%) displayed minimal axonal pathology (score 1), 6 cases (35 %) had 
moderate axonal pathology (score 2) and the final 5 cases (29%) displayed more extensive 
axonal pathology (score 3) (Fig. 7d). Thus, the overall extent of axonal pathology as 
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determined by APP IHC was greater than that identified with SNTF, of which a representative 
example is provided in Fig 7-b. However, SNTF positive axons were considerably more 
abundant in the human severe TBI cases when compared to the swine model of mTBI. 
Interestingly, cases of severe human TBI also displayed a degree of neuronal-dendritic 
immunoreactivity for SNTF, typically in neurons that appeared unhealthy or associated with 
focal lesions, consistent with previous observations of SNTF in more severe models of TBI 
[57]. 
 Of the control group just 2 of 16 (12.5%) cases displayed only minimal (score 1) SNTF 
immunoreactivity. Both of these cases also displayed APP accumulating axons and, similarly, 
SNTF was observed in the same regions as APP in a pattern and distribution in keeping with 
hypoxic/ischemic injury [19, 20, 27, 29, 34, 53]. Only one control was minimally APP positive 
yet displayed no SNTF reactivity. The cause of death in this case was acute paracetamol 
overdose. 
 As with swine studies, staining with independent antiserum for SNTF in human tissue 
revealed consistent patterns of immunoreactivity for axonal profiles with an injured morphology. 
There was no significant difference in the PM delay between TBI cases (Mean 50 hours; range 
3-120 hours) versus controls (mean 43 hours; range 4-120 hours) (TTEST: p=0.5). Moreover, 
in TBI cases, although numbers were small, there was no difference in the PM delay between 
those cases with absent or minimal immunoreactivity (score 0-1) versus those with moderate to 
extensive immunoreactivity (score 2-3) (TTEST: p=0.1). 
 
Comparison of APP and SNTF Immunoreactivity Following TBI in Humans: Double 
Labeling 
 As described above, fluorescent labeling revealed both SNTF and APP positive axons 
with abnormal morphologies including swollen, fusiform axons (varicosities) and terminal 
axonal bulbs (Fig. 9-10). Once again, there was not complete overlap between the axonal 
populations reactive for APP and SNTF. Reflective of the overall greater extent of APP 
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immunoreactivity described above, frequent morphologically abnormal APP immunoreactive 
axonal profiles were observed that had no demonstrable SNTF immunoreactivity. In addition, 
various other damaged axons displayed either complete or patchy co-localization of SNTF and 
APP. Rarely, damaged axons immunoreactive for SNTF only were observed (Fig. 9-10).  
 
Comparison of SNTF with APP and Neurofilament Subtypes as Markers of Axonal 
Pathology following TBI in Humans 
Dephosphorylated NF-H (SMI-32): Human tissue demonstrated normal immunoreactivity for 
SMI-32 in select subgroups of neurons, including both the cell body and axons consistent 
between TBI cases and controls as previously described in humans [14, 24] (Fig. 11a,I,k). In 
addition, baseline white matter immunoreactivity was also observed in selective axons. 
However, following TBI, SMI-32 immunohistochemistry revealed occasional abnormal profiles 
including minimal undulations and occasional granular accumulations in terminal bulbs in 
regions where APP positive axonal pathology was observed on serial sections (Fig. 11b-e,g). 
Nonetheless, the extent of readily identifiable pathology was minimal when compared to either 
SNTF or APP, in part exacerbated by the high degree of baseline SMI-32 immunoreactivity in 
neuronal soma, dendrites and axons making interpretation of more subtle swellings difficult to 
identify. 
Subsequent triple labeling studies with SMI-32, SNTF and APP demonstrated some overlap 
between limited SMI-32 positive swellings and either SNTF or APP. Notably, SNTF 
immunoreactivity was observed in isolated axons or components of axons, but also frequently 
co-localized with large APP positive swellings in the absence of SMI-32. While the pattern of 
overlapping markers was complex, only very occasional profiles could be observed with SMI-
32 immunoreactivity alone (Fig. 11e-h). 
NF-68: As above, human tissue demonstrated immunoreactivity for NF-68 in subgroups axons 
with a normal morphology consistent between both TBI cases and controls (Fig. 12a,h,j). 
However, virtually no immunoreactivity could be detected in neuronal cell bodies, consistent 
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with findings in swine and previous reports[24]. Following TBI, NF-68 revealed abnormal 
axonal profiles, although this was comparatively less that that identified using APP or SNTF on 
serial sections, and typically only in regions with extensive damage (Fig. 12b-d,f).  
This finding was supported in triple labeling studies with dephosphorylated NF-L, SNTF and 
APP, which demonstrated minimal overlap between SNTF or APP in both axonal swellings and 
varicose profiles. However, again, very occasional NF-68 swellings could be observed in the 
absence of APP or SNTF (Fig. 12d-g).  
Compacted Neurofilament-M (RMO-14): RMO-14 staining identified a subset of neurons, 
dendrites and axons with a normal morphology consistent between TBI cases and controls 
(Fig. 13a). Following TBI, in regions of axonal pathology, RMO-14 typically identified swollen 
axonal bulbs although again less that what was observed with APP (Fig. 13b-c,d,f,h,i). 
Nonetheless, the Triple labeling with RMO-14, SNTF and APP was compelling, demonstrating 
that SNTF and RMO-14 frequently co-localized to individual axonal bulbs. Interestingly, SNTF 
and RMO14 appeared to occupy distinct compartments within these bulbs. Notably, RMO-14 
very rarely co-localized with APP. In addition to this complex co-labeling, all 3 markers 
demonstrated injured axonal profiles, or components of varicose axons, positive for each 
individual marker alone (Fig. 13d-i). This indicated that all 3 markers can identify different 
populations of injured axons at a given time post TBI. 
 
Discussion 
Here we demonstrate that immunostaining for the calpain cleaved N-terminal fragment 
of alpha II spectrin, SNTF, may reveal a unique and previously unidentified subpopulation of 
injured axons following TBI. In the absence of tissue from humans following mTBI we 
examined a swine model of mTBI, where SNTF was found acutely in axons without large 
swellings, which were frequently distinct from injured axons marking for APP or neurofilament 
subtypes.  Following severe TBI in humans, while there was some overlap between the 
localization of SNTF and APP in swollen axon profiles, a small subset of SNTF positive axons 
Page 21 of 40 
displayed no APP accumulation. Moreover, while there was clear co-localization between 
SNTF and compacted neurofilament-M in damaged axons, other SNTF positive axons had no 
overlap. Interestingly, compacted neurofilament was also observed in injured axons without 
either APP or SNTF.  This suggests there might be multiple distinct phenotypes of axonal 
pathology post-TBI. SNTF positive axons may represent a unique phenotype of axonal injury, 
where degeneration is primarily due to proteolysis rather than following transport interruption. 
In addition, the identification of rapid and axon-specific accumulation of SNTF after TBI is 
consistent with the reported association of blood SNTF elevations and white matter 
abnormalities detectable with diffusion tensor imaging [62] and supports the potential diagnosis 
of DAI in individuals found to have elevated serum SNTF levels after mild TBI [62, 65]. 
Together these data may provide a novel approach to perform more comprehensive 
neuropathological analyses of DAI.  
The spectrin tetramer is an actin-binding component of the submembraneous cortical 
axonal skeleton important for normal development. In addition to playing a critical structural 
role, spectrin proteins have a complex physiological role in membrane function [4]. SNTF is a 
stable N-terminal 1176 residue fragment of the spectrin α-subunit generated via cleavage of 
alpha-II spectrin by calcium-dependent calpain proteases [54, 64]. In TBI, spectrin breakdown 
products have commonly been observed in multiple animal models [13, 42, 56, 57], suggesting 
that calcium influx is an important initial mediator of post-traumatic proteolysis. Indeed, massive 
calcium influx has been demonstrated to occur via both mechanically mediated ion channel 
dysfunction and alterations to membrane permeability [12, 33, 48, 49, 82]. Recently, an in vitro 
model of axonal injury directly demonstrated that calcium influx occurs with dynamic stretching 
of axons and leads to calpain activation, spectrin proteolysis and SNTF accumulation [33, 80, 
82]. 
Here we demonstrate the presence of SNTF within damaged axons following a clinically 
relevant model of mTBI in a time course consistent with observations of SNTF in the serum of 
CT-negative mTBI patients and sports-related concussion [62, 65]. Although mTBI or 
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“concussion” is a very common clinical designation, the underlying pathophysiology has 
remained unresolved, which, in turn, has precluded the development of objective diagnostic 
tests.  Nonetheless, there is increasing recognition that a key pathological substrate of mTBI is 
DAI [5-7, 40, 44, 81, 84].  Our data suggest that axons may be a primary source of SNTF in 
mTBI and provide a pathological correlate for the blood SNTF elevations that are linked 
mechanistically to axon degeneration [80]. Notably, no SNTF was observed in the neuronal 
somata or any other cell type at any experimental time-point post-mTBI. 
 The clinical relevance of observations in the swine model is supported by the direct 
demonstration of SNTF accumulation in humans following TBI. While the human tissue was 
derived from cases of severe TBI, it confirms that damaged axons are an important anatomical 
source of SNTF clinically. Notably, while in recent years there has been extensive efforts to 
develop advanced neuroimaging approaches for detecting DAI post-trauma, including in mTBI 
[31], there are currently no conventional non-invasive diagnostic tools capable of reliably 
identifying DAI, even in severe TBI. The identification of specific patho-anatomic markers of 
axonal degeneration such as SNTF, in both serum and injured axons, provides evidence that 
SNTF is a biologically plausible blood biomarker for mTBI, and lends support for the potential 
non-invasive diagnosis of DAI via a blood test for SNTF.   
In tissue derived from both the mTBI model and from severe TBI in humans, a subset of 
axons were identified as SNTF positive and APP negative. Yet the abundance of APP positive 
axons appeared far greater than that of SNTF positive axons in all cases. Notably, the 
quantification of exact numbers of injured axons using 8µm tissue sections is challenging. In 
particular, when comparing the typically large APP-immunoreactive swellings to those of the 
small and fragmented SNTF axons, standard approaches using percentage area or profile 
counts have limitations in respect of providing meaningful quantification of individual axon 
number.   For example, for counting profiles, swollen axons may travel in and out of plane in 
the same section or traverse multiple sections resulting in an exaggerated overall count. As 
such, we performed a standardized, semi-quantitative evaluation. Based on these analyses, we 
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would estimate that, although variable, SNTF pathology presents approximately 10% or less of 
that revealed with APP.  
In addition, while the number of animals examined was small, the pathology observed was clear 
at all time points and completely absent in controls. As such, this cohort provides compelling 
initial findings regarding the potential mechanisms of axonal degeneration and diagnosis. 
However, future large enough to permit delineation of the temporal course of immunoreactivity 
patterns are indicated. 
 Nonetheless, together these data indicate that while SNTF IHC is not as sensitive for 
the detection of transport-interrupted axons, it may represent a specific subset of pathological 
axons, and presents the intriguing possibility that these axons are capable of degenerating via 
a distinct pathway independent of transport interruption. Indeed, while there has been a focus 
on axonal swelling leading to degeneration, calpain mediated proteolysis is part of the 
spectrum of injury that may be critical for determining outcome. Notably, the morphology of 
SNTF axons in our animal model was frequently different from that of APP positive axons, 
being smaller in diameter and much more rarely displaying fusiform or varicose swellings, 
consistent with an absence of transport interruption. Interestingly, this morphology of SNTF 
positive axons also evolved over time. Typically axons were intact and had an undulating 
appearance at 6 hours, a morphology that has previously been shown to occur immediately 
following dynamic axonal stretch in vitro and is associated with microtubule breakage [78, 79].  
However, by 3 days post-injury, SNTF positive axons developed a beaded appearance 
indicative of degeneration, yet many remained without noticeable swelling or APP 
accumulation.   
Given the lack of co-localization with APP in a proportion of injured axons, further 
experiments were performed to examine for potential co-localization with other previously 
identified markers of axonal pathology. Notably, while others and we historically used NF 
based markers of axonal pathology, these were largely replaced with APP IHC upon 
demonstration that it can detect a greater extent of pathology and at very early time points. 
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Nonetheless, previous work by Povlishock and colleagues indicates that cytoskeletal injury to 
axons can occur without detectable transport interruption as indicated by experimental rodent 
models showing neurofilament (NF) compaction in the absence of APP accumulation [38, 77]. 
Our findings are largely consistent with what was observed in the rodent and confirm this 
finding for the first time in human material. Specifically, we observed a curious pattern of co-
localization between SNTF and RMO14 positive axons that were APP negative. In addition, all 
3 makers could be observed independently. These data support the premise that there are at 
least 3 distinct populations of injured axons post-TBI in humans and following mTBI in swine, 
highlighting the complex pathophysiology of axonal degeneration. Notably, while ultrastructural 
analyses were not possible in this study, examination of the subcellular localization of the 
various markers of axonal pathology, including APP, SNTF and RMO-14 may provide 
additional important information regarding mechanisms of axonal degeneration. 
Examination for co-localization between SNTF, APP and either SMI-32 or NF-68, 
yielded data that were less compelling than for RMO14. As has been described previously, NF-
68 proved to be a more useful marker of axonal pathology than SMI-32 in both swine and 
humans, although it was very limited when compared to APP. Moreover, while there was some 
co-localization between, NF-68 also appeared to identify a distinct population of injured axons 
from both SNTF and APP, although this population was small. An important limitation of all NF 
based markers is that there is a degree of baseline staining in normal axons. As such, 
contrasting with SNTF, the presence of positive NF staining alone is not indicative of pathology. 
As such, the presence of pathology is dependent upon the identification of axons with an 
abnormal morphology which can limit the identification of more subtle changes e.g. a swollen 
axon of small diameter can look like that of a normal large diameter axon if identified in the 
appropriate plane of sectioning. 
 While the reasons that SNTF positive axons fail to display markers of transport 
interruption are unclear, the observed rapid degeneration of SNTF positive axons by 48-72 
hours in mTBI may indicate a more severe form of axonal perturbation. Previous studies and 
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the current data clearly demonstrate that there is a wide array of morphological alterations in 
injured axons and their degenerative courses in any given injured white matter tract [12, 28, 34, 
35, 70], which may reflect the spectrum of injury severity. For example, in mild forms of axonal 
injury, there may not be evidence of swelling or proteolysis, but these axons may nonetheless 
be rendered dysfunctional due to ionic perturbations. At more moderate levels of injury, 
physical damage may result in axonal transport interruption and accumulation of cargoes, such 
as APP.  This range of damage may extend from minor and potentially reversible APP 
accumulation, to large swellings that cause secondary disconnection.  However, for the most 
severely injured axons, it is possible that the same marked ionic imbalance that leads to SNTF 
genesis also induces profound mitochondrial dysfunction and energy failure [11, 46, 47], thus 
preventing transport in these catastrophically injured regions.  This complete failure of 
transport, with no opportunity for extensive protein accumulation, accompanied by calcium-
mediated proteolysis may induce rapid disintegration.  Potentially, SNTF may be a marker for 
this severe form of axonal damage.  
While the severity of injury to axons is dependent on the mechanics of trauma [21, 35, 
43, 73], it is also possible that individual axons have selective vulnerability to mechanical injury 
due to their inherent structural or physiological properties. It will be of interest to further 
elucidate whether factors such as myelination status and caliber, previously shown to influence 
vulnerability to injury [52, 75], are significant in determining SNTF positivity. Understanding the 
differential responses of axons to trauma will provide potentially novel approaches to 
developing targeted interventions. 
Notably, the morphological differences between SNTF and APP immunoreactivity were 
less apparent in human tissue following severe TBI, which displayed a wide range of SNTF 
positive axonal morphologies, including both small and large diameter axons, as well terminal 
bulbs and fusiform profiles. The reasons for the morphological differences between the mTBI 
model and severe TBI in humans likely reflects the much more complex, heterogeneous and 
evolving axonal pathologies following severe TBI in humans when compared to the controlled, 
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less severe model employed here. Indeed, the swine model at the head rotational levels used 
in this study produces a very pure diffuse axonal pathology in a biomechanical distribution, 
without comorbid hemorrhagic or focal lesions, brain swelling or raised ICP. Severe TBI in 
humans often results in axonal pathology with complex, variable morphologies with differing 
distributions when identified using APP IHC [34, 35]. Notably, prolonged ischemia or brain 
swelling due to non-traumatic etiologies can also result in this pattern of APP immunoreactive 
axonal pathology and has been observed in approximately 20% of non-selected post-mortem 
cases without TBI [34].  
The observation that SNTF can be observed relatively acutely post-trauma (within 
hours), suggests that it is likely accumulating at the site of mechanical injury. However, the 
more mixed pattern of overlap with APP and more complex overall pattern and distributions in 
human severe TBI indicate that SNTF reactivity can occur via multiple mechanisms, possibly 
independent of traumatic forces and likely downstream from multiple mechanisms of calcium 
dysregulation. Nonetheless, utilizing SNTF as a marker of axonal injury in combination with 
APP and RMO14 alone, clearly identified a greater extent of pathology than either marker 
alone, indicating potential utility in the clinical neuropathological assessment of axonal 
pathology. 
Here we present data that provides an important anatomic and mechanistic substrate 
for SNTF as a clinically relevant biomarker of axonal injury. In addition, in tissue derived from 
both the mTBI model and post-mortem cases of TBI, the combined use of both SNTF, RMO14 
and APP IHC offers a more comprehensive assessment of DAI. Moreover, as SNTF positive 
axons may represent a more severe form of pathology, the relative immunoreactivity of these 
markers may permit a more detailed quantitative neuropathological assessment of injury 
severity and response to therapeutic intervention in the acute phase.  
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Table 1. Demographic and Clinical Data for all Post-Mortem Cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Demographic and Clinical Data 
 TBI Cases 
(n=18) 
Controls 
(n=16) 
Age  Mean 
(Range) 
44.1 years 
(16-59 years) 
43.0 years 
(16-60 years) 
Median 51 years 49 years 
Males  10 (55.6%) 10 (64.7%) 
  
Mean Survival Time 
(Range)  
1.5 days  
(6 hours-7 
days 
Not Applicable 
Median Survival Time 2.3 days Not Applicable 
Mean Post-Mortem Delay 50 hours 
(3-120 hours) 
43 hours 
(4-120 hours) 
 Assault 3 (17%) Not Applicable – 
All control cases 
has no known 
history of TBI 
Fall 10 (55%) 
MVC 5 (28%) 
Cause of Death 
TBI 17 (95%) 0(0%) 
Bronchopneumonia / ARDS  1 (5%) 1 (6.3%) 
Sudden Unexpected Death 
Due to Epilepsy 
0 (0%) 3 (18.8%) 
Acute Cardiovascular Death 0 (0%) 4 (25.0%) 
Inhalation Gastric Contents 0 (0%) 1 (6.3%) 
Drug Overdose 
(paracetamol/coproxamol) 
0 (0%) 1 (6.3%) 
Acute Death associated with 
amphetamine  
0 (0%) 1 (6.3%) 
Bronchopneumonia 
secondary to malignancy 
0 (0%) 2 (12.5%) 
Non-Hodgkin’s Lymphoma  0 (0%) 1 (6.3%) 
Septicemia 0 (0%) 2 (12.5%) 
ARDS = acute respiratory distress syndrome; MVC = motor vehicle 
collision. 
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Figure Legend 
Fig. 1 
APP (antibody 22C11) accumulation in injured axons following rotational acceleration-
deceleration injury in swine. (a) Whole brain coronal map of APP accumulating axonal 
pathology 48 hours following injury. (b) Low power view of diffuse APP positive axonal bulbs 
and fusiform swellings the subcortical white matter of the left hemisphere 48 hours following 
injury. Scale bar 100µm. (c) Extensive APP positive axonal bulbs and swellings in the 
periventricular white matter 6 hours following injury. Note the associated disruption of the 
ependymal cell layer. Scale bar 25µm. (d) APP accumulating axons 48 hours following injury 
displaying a variety of injured morphologies including terminal swellings, beading and intact 
fusiform profiles with multiple points of transport interruption. Scale bar 25µm.   (e) A single 
APP positive injured axon 6 hours post injury with APP accumulating along its length and 
giving a fusiform appearance. Note the largest point of swelling is followed by a section of the 
axon with a much narrower diameter and beaded appearance likely indicative of complete 
transport interruption with distal Wallerian-like degeneration. Scale bar 25µm. (f) A single APP 
positive degenerating axon underlying a vessel at 48 hours post-injury, a common site of 
axonal pathology likely reflecting the impingement of axons on the comparatively more rigid 
vessel during dynamic motions. Scale bar 25µm. (g) A highly fusiform APP positive axon 48 
hours post injury indicating multiple points of cytoskeletal damage and transport interruption. 
Scale bar 25µm. (g) Extensive APP positive axonal pathology in the periventricular white 
matter 72 hours following injury with densely packed swellings. Scale bar 100µm   
  
Fig. 2 
IHC specific for SNTF (Ab2233) showing the range of axonal pathologies following rapid 
rotational acceleration deceleration in swine. (a) An absence of SNTF immunoreactivity in the 
subcortical white matter of a sham animal. (b) Multiple SNTF positive profiles in the subcortical 
white matter of the left hemisphere 6 hours post injury. Note that the axons are of 
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comparatively smaller diameter to those reactive for APP with limited evidence of extensive 
swelling. (c). A single axon reactive for SNTF 6 hours post-injury in the periventricular region 
which remains intact along the immunoreactive portion without overt swellings. (d) A single 
axon reactive for SNTF 6 hours post-injury in the subcortical white matter with a more patchy 
immunoreactivity extending approximately 100µm. (e) A single SNTF positive axon 6 hours 
post-injury in the left subcortical white matter showing an undulating morphology indicative of 
cytoskeletal damage with an absence of large swellings. (f) 48 hours post-injury, a single SNTF 
positive axon with some small swellings and a more degenerative morphology. (g) A single 
SNTF positive axon at 72 hours post-injury in the subcortical white matter showing a highly 
beaded and degenerative morphology. (h) An absence of SNTF positive profiles in the 
periventricular region of a sham. (i) The same region as (h) showing multiple small 
accumulations of SNTF 48 hours post-injury. (j) An axon positive for SNTF close to a vessel, a 
known site of mechanical vulnerability. (k) What appears to be a single SNTF positive axon 
with multiple foci of SNTF immunoreactivity extending for several hundred microns through the 
subcortical white matter 72 hours post-injury in a region of known mechanical vulnerability. (l) 
Semi quantitative scoring of APP pathology versus SNTF pathology following the model of 
mTBI. All scale bars 25µm  
 
Fig. 3 
Double label IHC following following rapid rotational acceleration / deceleration in swine using 
APP (22C11) and SNTF (Ab2233). (a-c) A region of the subcortical white matter showing APP 
and SNTF reactive profiles with notably little overlap at 72 hours post-injury. (d-f) An APP 
immunoreactive axonal swelling that is SNTF negative and (g-i) SNTF immunoreactive axonal 
profile that is APP negative at 48 hours post-injury. Note the significantly reduced diameter of 
the SNTF positive axon. (j-l, m-o) SNTF reactive profiles that are also immunoreactive for pan-
NF-H (Sigma) confirming that they are axons. All scale bars 25µm 
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Fig. 4 
Representative example of triple immunofluorescent labeling following mTBI in swine: (a) 
Merged image (b) SNTF (red), (c) SMI-32 (green) and (d) APP (purple). (e-f) demonstrate high 
magnification of regions identified with arrows in (a).  Note that while there is overlap with 
SNTF in SMI-32 positive axons, they appeared to have a normal morphology without swellings 
(f). In addition, APP positive swellings did not co-localize with SMI-32 (e). Notably, many SNTF 
axons did not co-localize with either SMI-32 or APP (g). All scale bars 100µm 
 
Fig. 5 
NF-68 staining in sham animal (a) and following mTBI in swine (b-c). Note the clear baseline 
staining in normal axons in shams (a). In contrast, large swollen axonal bulbs could be seen 
post-mTBI (b-c). 
Representative example of triple immunofluorescent labeling in swine with SNTF (red), NF-68 
(green) and APP (purple). At 6 hours post-mTBI there are very few NF-68 positive swellings 
although APP and SNTF accumulating profiles can be observed without co-localization (d-g). In 
contrast, by 48 hours, clear NF-68 positive swellings can be observed (h-k), few of which co-
localized with APP and or SNTF (h,arrow). However, many injured axons displayed no-co-
localization between any markers (h-k). In contrast, shams displayed no APP or SNTF positive 
staining, but clear baseline NF-68 in axons was visible (l-o). All scale bars 100µm 
 
Fig. 6 
RMO14 staining in (a) sham animal and following mTBI in swine (b-c). Note the clear baseline 
staining in shams (a). In contrast, large swollen axonal bulbs could be seen post-mTBI (b-c). 
Representative example of triple immunofluorescent labeling in swine with SNTF (red), RMO14 
(green) and APP (purple) at 48 hours post-mTBI (d-g). RMO14 positive swellings can be 
observed, with (arrows) and without co-localization with APP and SNTF (d-g).  However, many 
injured axons displayed no-co-localization between any markers. Note the more subtle beaded 
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profiles positive for SNTF alone (e, arrowhead). Sham animals displayed no APP or SNTF 
positive staining, but clear baseline RM014 in axons was visible (h-k). All scale bars 100µm 
 
Fig 7. 
SNTF (Ab2233) versus APP (22C11) immunoreactivity acutely following severe TBI in humans.  
APP (a) and SNTF (b) immunoreactive profiles including fusiform swellings and terminal axonal 
bulbs in serial sections of the white matter adjacent to the cingulated gyrus in an 18 year old 
male who died 10 hours following severe TBI. Note the more extensive pathology revealed by 
APP IHC. Graphs showing semi-quantitative scores for the percentage of cases with APP (d) 
and SNTF (e) immunoreactive axonal profiles 
 Scale bars 100µm 
 
Fig 8. 
The range of SNTF (Ab2233) immunoreactive profiles in white matter following acute severe 
TBI in humans. (a-b) SNTF immunoreactive axons with an undulating morphology in the 
parasagittal white matter of a 59 year old male, 4 days following a TBI caused by a fall. Scale 
bars 50µm. (c) Swollen and fusiform SNTF immunoreactive profiles in the corpus callosum of 
an 18 year old male who died 10 hours following TBI as a result of a violent assault involving 
blunt force trauma to the head. Scale bar 100µm.  (d) SNTF immunoreactive terminal axonal 
bulbs and (e) a linear SNTF positive, swollen axonal profile observed in the corpus callosum of 
a 17 year old male who died 2 weeks following a road traffic accident. Scale bars 50µm 
 
Fig. 9 
SNTF (Ab2233) and APP (22C11) double labeling acutely following severe TBI in humans. 
SNTF (red) and APP (green) immunoreactivity in (a-c) an 18 year old male who died 10 hours 
following TBI as a result of a violent assault involving blunt force trauma to the head (same 
case as displayed in Figs. 1c and 2). (d-f) 41 year old male who died 20 hours post-TBI caused 
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by a fall. In both instances, note the mixed population of axons immunoreactive for APP or 
SNTF only versus those where SNTF and APP co-localize. Scale bars: (a-c) 100 µm, (d-f) 
50µm 
 
Fig. 10 
SNTF (Ab2233) and APP (22C11) double labeling acutely following severe TBI in humans. 
SNTF (red) and APP (green) immunoreactivity in (a-f) 18 year old male, 10 hours survival 
(same case as displayed in Figs. 1c, 2, 5). (g-i) 41 year old male who died 20 hours post-TBI 
(same case as Fig. 5d-f). (a-c) Shows patchy variation in the extent of APP and SNTF 
immunoreactivity along the length of a fusiform axon. (d-f) shows almost complete overlap in 
SNTF and APP immunoreactivity in a large axonal swelling which remains connected. (g-h) 
Shows axons that are both reactive for either APP or SNTF only, in addition to those with co-
localization. All scale bars: 25µm 
 
Fig. 11 
SMI-32 staining in humans demonstrating baseline staining in (a) a normal control case versus 
the occasional scattered axons with altered morphology, including greatly swollen terminal 
bulbs, following acute severe TBI (b-e). Representative example of triple immunofluorescent 
labeling in human white matter with SNTF (red), SMI-32 (green) and APP (purple). Following 
TBI (e-h), SMI-32 swollen profiles were few in comparison to that identified by APP or SNTF 
and can be difficult to interpret given the baseline staining in normal axons. Complex patterns 
of co-localization can be observed (e-h). SNTF frequently co-localizes with APP and more 
occasionally SMI-32. However, SNTF and APP profiles can be observed without co-
localization.  
In contrast, controls displayed no APP or SNTF positive staining, but clear baseline SMI-32 
immunoreactivity was visible in axons (i-l). 
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Fig. 12 
NF-68 staining in human cases demonstrating baseline staining in (a) a normal control when 
compared to acute severe TBI cases that displayed occasional swollen terminal bulbs (b) and 
axons with a altered or undulating morphology (c). Representative example of triple 
immunofluorescent labeling in humans with SNTF (red), NF-68 (green) and APP (purple). 
Following TBI (d-f), NF-68 swollen profiles were few in comparison to that identified by APP or 
SNTF. SNTF frequently co-localizes with APP and only occasional co-localization with NF-68 
could be observed. However, again SNTF and APP profiles can be observed without co-
localization.  
In contrast, controls displayed no APP or SNTF positive staining, but clear baseline NF-68 
immunoreactivity was observed in axons(i-l). 
 
Fig. 13 
RMO immunoreactivity demonstrating normal white matter staining in (a) a normal control 
when compared to human cases of acute TBI (b-c). TBI cases displayed altered axonal 
morphologies including undulations and terminal axonal bulbs. 
Representative examples of triple immunofluorescent labeling in humans showing SNTF (red), 
RMO13 (green) and APP (purple) (d-m). Following TBI (d-i), RMO14 swollen profiles were 
observed (d,f,h,i). Notably, SNTF often co-localized with RMO14, although they appeared to 
occupy different compartments within terminal axonal bulbs (d,h). There was also little overlap 
with between RMO14 and APP. Again SNTF and APP profiles were be observed without co-
localization with any other markers.  
In contrast, controls displayed no APP or SNTF positive staining, but clear baseline RMO14 
immunoreactivity was observed in axons (j-m). 
 
 
 
